Business Context and Reporting Period
Company: Qualigen Therapeutics, Inc. (Note: Input metadata referenced "Aixcrypto Holdings," but the filing text identifies the registrant as Qualigen Therapeutics, Inc., trading as QLGN).
Reporting Period: Quarterly period ended September 30, 2025 (Form 10-Q).
Business Overview: Qualigen is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. Its primary programs include QN-302 (pancreatic cancer) and Pan-RAS (preclinical). In September 2025, the company consummated a $41.0 million offering led by Faraday Future Intelligent Electric Inc. (FFAI). Proceeds are designated to pay existing debt, fund operations, and establish a cryptocurrency treasury operation.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(2,037,819) | $(6,369,407) | $(5,403,368) |
| Net Loss Attributable to Common | $(2,905,615) | $(7,238,789) | $(5,490,972) |
| EPS (Basic & Diluted) | $(4.68) | $(4.35) | $(24.93) |
| Cash and Cash Equivalents (End of Period) | $38,777,166 | $38,777,166 | $388,152 |
| Operating Cash Flow | N/A | $(4,828,985) | $(4,057,980) |
| Total Current Liabilities | $4,923,286 | $4,923,286 | $2,007,483 |
| Accumulated Deficit | $(129,430,981) | $(129,430,981) | $(123,061,575) |
Material Changes vs. Prior Period
- Liquidity Surge: Cash balances increased from $1.17 million at December 31, 2024, to $38.78 million at September 30, 2025, driven by a $41.0 million equity offering in September 2025.
- Expense Fluctuations: General and Administrative (G&A) expenses increased 72% quarter-over-quarter (Q3 2025 vs. Q3 2024) to $1.89 million, primarily due to professional fees for audits and investor relations. However, Research and Development (R&D) expenses decreased 15% to $105,576 as clinical development was slowed.
- Debt Structure: The company issued short-term promissory notes totaling $3.64 million between January and July 2025. Current liabilities include $2.9 million in promissory notes and $340,000 in convertible debt.
- Non-Operating Items: The company recorded a $567,000 credit loss expense (reversal of provision) related to short-term notes receivable in Q3 2025. Significant losses were also recorded on the change in fair value of warrant liabilities ($148k) and convertible debt ($198k).
Guidance, Outlook, Risks, and Contingencies
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for the one-year period following the report date. While cash is high, a significant portion ($37.7 million net proceeds) is restricted for cryptocurrency treasury operations and debt repayment, leaving limited liquidity for immediate operations.
- Strategic Pivot: The company is establishing cryptocurrency treasury operations using AlxCrypto. There are no guarantees this new venture will generate revenue.
- Operational Slowdown: Development of therapeutic products (QN-302 and Pan-RAS) has been slowed due to financial constraints. Management plans to ramp up development only when properly funded.
- Legal Contingencies: A lawsuit with LifeSci Capital LLC regarding unpaid placement agent fees was settled in October 2025 for $75,000 (accrued as of Sept 30).
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, citing material weaknesses including insufficient accounting personnel, lack of IT general controls, and absence of formalized documentation.
Investor Verification Checklist
- Cash Availability: Verify the actual availability of the $38.8 million cash balance, as a large portion is earmarked for cryptocurrency operations and debt repayment, potentially limiting operational runway.
- Cryptocurrency Strategy: Assess the viability and risk profile of the new cryptocurrency treasury operations, which are unproven and carry significant market risk.
- Debt Obligations: Review the terms of the $2.9 million in promissory notes, specifically the 30% premium due on repayment and maturity dates (six months from issuance).
- Internal Controls: Evaluate the timeline and cost required to remediate the identified material weaknesses in internal controls over financial reporting.
- Marizyme Exposure: Monitor the $4.35 million short-term note receivable from Marizyme, which carries an 18% interest rate but has a $261,000 allowance for credit losses.